Yuichi Tominaga

A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1

Takahiro Oike, Hideaki Ogiwara, Yuichi Tominaga et al. · Cancer Research · 2013 · 292 citations · Full text

Fgfr1 Gene Amplifications, Treat Cancers, Tumor Biology +19

Targeting p300 Addiction in <i>CBP</i> -Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of <i>MYC</i> Expression

Hideaki Ogiwara, Mariko Sasaki, Takafumi Mitachi et al. · Cancer Discovery · 2015 · 179 citations · Full text

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 135 citations · Full text

Deformation capability of poly(tetrafluoroethylene) materials: Estimation with X-ray diffraction measurements

Kimiyasu Sato, Yuichi Tominaga, Yusuke Imai et al. · Polymer Testing · 2022 · 59 citations · Full text

Inhibition of Hsp90 Leads to Cell Cycle Arrest and Apoptosis in Human Malignant Pleural Mesothelioma

Junichi Okamoto, Iwao Mikami, Yuichi Tominaga et al. · Journal of Thoracic Oncology · 2008 · 56 citations · Full text

Hsp90 Leads, Medicine, Apoptosis +9